Accrol to Release Half Year results on 30 January; online investor presentation on 2 February

Accrol Group Holdings plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Accrol Group Holdings plc (LON:ACRL), the UK’s leading independent tissue converter, will release its Half Year Results for the six months to 31 October 2023 on Tuesday 30 January 2024.

As part of Accrol Group’s Results roadshow, the management will host an online investor presentation and Q&A session. This will take place on Friday, 2 February 2024 at 1.30pm. Anyone wishing to participate should register for the event with PI World at: https://bit.ly/ACRL_H124_results_webinar.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Accrol Group Holdings plc (LON:ACRL) has announced the publication of a shareholder circular detailing terms of the Scheme. Learn more here.
Discover the latest results and overview of Accrol Group Holdings, the UK's top independent tissue converter, led by CEO Gareth Jenkins and CFO Chris Welsh.
In this interview, Gervais Williams, co-fund manager of Miton UK MicroCap Trust, discusses navigating the economic landscape and standout companies in 2024. Find out more here. #investment #microcap
Accrol Group Holdings plc has reported strong H1 FY24 results, with impressive growth in adjusted EBITDA and adjusted PBT. The company remains on track to meet expectations and has seen gains in market share. Furthermore, the private label segment of the UK tissue market continues to increase, and the sales of biodegradable wet wipes have been exceptionally strong. Accrol's outlook remains positive with expected further volume growth.
Accrol Group Holdings plc has reported strong performance in H1 FY24, with branded volumes rising by 45% and margins returning to pre-pandemic levels. The group is on track to deliver FY24 results in line with expectations and expects to outperform previous expectations for FY25.

Search

Search